EIT Pharma

CompanyUnited States

EIT Pharma develops one asset, approved (lonafarnib in laminopathy). Mostly small molecule acting on FNTB and FNTA; based in the United States.

1
Asset
Furthest stage: Approved
Raised: $35M; 3
Trials: 4
Signals

Pipeline

1

lonafarnib
Inhibits farnesyltransferase, preventing protein farnesylation.
Approved, Small molecule, FNTB, FNTA, laminopathy, progeria

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms3
Trials3
Funding rounds and grants1
Signals11
Similar companies6